Science Inventory

Continuing Development of Alternative High-Throughput Screens to Determine Endocrine Disruption, Focusing on Androgen Receptor, Steroidogenesis, and Thyroid Pathways

Citation:

Continuing Development of Alternative High-Throughput Screens to Determine Endocrine Disruption, Focusing on Androgen Receptor, Steroidogenesis, and Thyroid Pathways.

Impact/Purpose:

The United States EPA's Endocrine Disruptor Screening Program uses appropriate validated test systems and other scientifically-relevant information to screen and test for endocrine disrupting chemicals. Since the issuance of the Federal Register Notice (entitled, “Use of High Throughput Assays and Computational Tools; Endocrine Disruptor Screening Program; Notice of Availability and Opportunity for Comment”) on June 19, 2015 (FRL-9928-69), EPA has continued the development of high throughput assays and computational tools for both the detection of the potential to disrupt the endocrine system, as well as to estimate levels of exposure. The use of these methods will accelerate the pace of screening, reduce animal testing, and significantly decrease costs associated with screening.

Description:

The focus of this meeting is the SAP's review and comment on the Agency's proposed high-throughput computational model of androgen receptor pathway activity as an alternative to the current Tier 1 androgen receptor assay (OCSPP 890.1150: Androgen Receptor Binding Rat Prostate Cytosol). Additionally, the SAP will assess the Agency's progress in the development of a high-throughput model of steroidogenesis to be used as an alternative to the current Tier 1 steroidogenesis assay (OCSPP 890.1550: Steroidogenesis Human Cell Line—H295R); and proposed adverse outcome pathway-based framework for screening chemicals for potential thyroid disruption.

Record Details:

Record Type:DOCUMENT( ASSESSMENT DOCUMENT)
Record Released:12/04/2017
Record Last Revised:07/28/2022
OMB Category:Influential
Record ID: 338571